Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Onconova Therapeutic (ONTX)
Onconova Therapeutic (ONTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,164
  • Shares Outstanding, K 20,970
  • Annual Sales, $ 230 K
  • Annual Income, $ -18,960 K
  • 60-Month Beta 1.78
  • Price/Sales 109.49
  • Price/Cash Flow N/A
  • Price/Book 1.08
Trade ONTX with:

Options Overview Details

View History
  • Implied Volatility 489.21% ( +68.71%)
  • Historical Volatility 167.58%
  • IV Percentile 79%
  • IV Rank 38.15%
  • IV High 1,211.82% on 03/15/23
  • IV Low 43.55% on 08/19/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 33
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 1,012
  • Open Int (30-Day) 1,214

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -52.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0800 +11.11%
on 05/26/23
1.4500 -17.24%
on 05/08/23
+0.1300 (+12.15%)
since 05/02/23
3-Month
0.6500 +84.62%
on 04/13/23
1.4500 -17.24%
on 05/08/23
+0.4069 (+51.31%)
since 03/02/23
52-Week
0.6200 +93.55%
on 12/30/22
1.5200 -21.05%
on 08/05/22
-0.1400 (-10.45%)
since 06/02/22

Most Recent Stories

More News
ProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue Estimates

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 130% and 18.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PRPH : 8.58 (-6.23%)
ONTX : 1.2000 (+1.69%)
Onconova Therapeutics, Inc. (ONTX) Reports Q3 Loss, Misses Revenue Estimates

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -23.81% and 5%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

ONTX : 1.2000 (+1.69%)
UPH : 1.5300 (-4.38%)
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

RXRX : 8.23 (-6.16%)
ONTX : 1.2000 (+1.69%)
Profound Medical (PROF) Reports Q2 Loss, Tops Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 6.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PROF : 13.39 (+10.30%)
ONTX : 1.2000 (+1.69%)
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022...

ONTX : 1.2000 (+1.69%)
Onconova Therapeutics Announces Key Management Promotions

Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of...

ONTX : 1.2000 (+1.69%)
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models

In vitro and cell-based assays suggest narazaciclib’s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6...

ONTX : 1.2000 (+1.69%)
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.

SNY : 51.01 (+1.09%)
RGLS : 1.3000 (-2.26%)
ONTX : 1.2000 (+1.69%)
SLNO : 5.95 (+1.21%)
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today...

ONTX : 1.2000 (+1.69%)
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

CPRX : 11.55 (-0.77%)
GALT : 1.5700 (-1.26%)
ONTX : 1.2000 (+1.69%)
SLNO : 5.95 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV,...

See More

Key Turning Points

3rd Resistance Point 1.2748
2nd Resistance Point 1.2479
1st Resistance Point 1.2239
Last Price 1.2000
1st Support Level 1.1730
2nd Support Level 1.1461
3rd Support Level 1.1221

See More

52-Week High 1.5200
Last Price 1.2000
Fibonacci 61.8% 1.1762
Fibonacci 50% 1.0700
Fibonacci 38.2% 0.9638
52-Week Low 0.6200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar